Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17,374 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Significance of C4d deposition in antibody-mediated rejection.
Takeda A, Otsuka Y, Horike K, Inaguma D, Hiramitsu T, Yamamoto T, Nanmoku K, Goto N, Watarai Y, Uchida K, Morozumi K, Kobayashi T. Takeda A, et al. Among authors: yamamoto t. Clin Transplant. 2012 Jul;26 Suppl 24:43-8. doi: 10.1111/j.1399-0012.2012.01642.x. Clin Transplant. 2012. PMID: 22747475
Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches.
Yamanaga S, Watarai Y, Yamamoto T, Tsujita M, Hiramitsu T, Nanmoku K, Goto N, Takeda A, Morozumi K, Katayama A, Saji H, Uchida K, Kobayashi T. Yamanaga S, et al. Among authors: yamamoto t. Hum Immunol. 2013 Sep;74(9):1111-8. doi: 10.1016/j.humimm.2013.06.022. Epub 2013 Jun 18. Hum Immunol. 2013. PMID: 23792054
5-year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: Retrospective single center assessment.
Hiramitsu T, Okada M, Futamura K, Yamamoto T, Tsujita M, Goto N, Narumi S, Watarai Y, Takeda A, Iwasaki K, Uchida K, Kobayashi T. Hiramitsu T, et al. Among authors: yamamoto t. Int Immunopharmacol. 2016 Oct;39:192-198. doi: 10.1016/j.intimp.2016.07.019. Epub 2016 Aug 2. Int Immunopharmacol. 2016. PMID: 27491025 Clinical Trial.
Favorable results in ABO-incompatible renal transplantation without B cell-targeted therapy: Advantages and disadvantages of rituximab pretreatment.
Okada M, Watarai Y, Iwasaki K, Murotani K, Futamura K, Yamamoto T, Hiramitsu T, Tsujita M, Goto N, Narumi S, Takeda A, Morozumi K, Uchida K, Kobayashi T. Okada M, et al. Among authors: yamamoto t. Clin Transplant. 2017 Oct;31(10). doi: 10.1111/ctr.13071. Epub 2017 Aug 29. Clin Transplant. 2017. PMID: 28792635
17,374 results
You have reached the last available page of results. Please see the User Guide for more information.